ANDA 76291, held by Watson Labs. Ipratropium Bromide.
As of Nov 15, 2026, ANDA 76291 (Ipratropium Bromide), held by Watson Labs, was first approved by FDA on May 9, 2005, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 9, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ipratropium Bromide0.02% ยท solution;inhalation | Ipratropium Bromide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
